Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2021.04.030
- Author:
Sun-Qiu XU
1
;
Pan ZHAO
1
;
Zhi-Hui WANG
1
;
Hong DENG
1
;
Liang ZHANG
1
;
Jin WEI
1
;
Xing-Li ZOU
2
Author Information
1. Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China.
2. Department of Hematology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China,E-mail: zxldylan@nsmc.edu.cn.
- Publication Type:Journal Article
- MeSH:
Bortezomib;
Humans;
Middle Aged;
Multiple Myeloma;
Prognosis;
Retrospective Studies;
Uric Acid
- From:
Journal of Experimental Hematology
2021;29(4):1216-1223
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the predictive value of pre-treatment serum uric acid (sUA) level for the prognosis of newly diagnosed multiple myeloma (NDMM) patients.
METHODS:The NDMM patients admitted to our center from January 2014 to December 2018 were analyzed retrospectively, and 94 patients among them who were initially treated with bortezomib-based chemotherapy for at least 4 cycles were included in this study. Clinical characteristics, laboratory data and follow-up information were collected, and the predictive value of sUA on the overall survival (OS) of NDMM was evaluated by using receiver operating characteristic (ROC) curve based on the patient's pre-treatment sUA level and the survival status at the end of follow-up, and the correlation of the sUA level with patient's clinical, laboratory characteristics and overall survival (OS) was further analyzed. The univariate and multivariate Cox proportional-hazards model were used to identify the potential factors affecting OS.
RESULTS:ROC analysis showed that the area under the curve for predicting OS in NDMM patients with sUA level was 0.702 (P<0.001), and the optimal cut-off value was 455.4 μmol/L. Compared to patients with low sUA (<455.4 μmol/L), patients with higher sUA (≥455.4 μmol/L) were more likely to have international staging system (ISS) stage III disease, beta2-microglobulin (β
CONCLUSION:Pre-treatment sUA level is a potential biomarker for the prognosis evaluation in NDMM patients, which deserves a further exploration and verification.
